Zai Lab Ltd. ADR (ZLAB): Price and Financial Metrics

Zai Lab Ltd. ADR (ZLAB): $33.40

2.62 (+8.51%)

POWR Rating

Component Grades








Add ZLAB to Watchlist
Sign Up

Industry: China




#31 of 46

in industry

ZLAB Price/Volume Stats

Current price $33.40 52-week high $53.95
Prev. close $30.78 52-week low $20.98
Day low $32.01 Volume 1,004,550
Day high $33.96 Avg. volume 664,122
50-day MA $34.47 Dividend yield N/A
200-day MA $36.45 Market Cap 3.27B

ZLAB Stock Price Chart Interactive Chart >


  • ZLAB scores best on the Sentiment dimension, with a Sentiment rank ahead of 84.61% of US stocks.
  • ZLAB's strongest trending metric is Sentiment; it's been moving up over the last 179 days.
  • ZLAB's current lowest rank is in the Quality metric (where it is better than 8.89% of US stocks).

ZLAB Stock Summary

  • For ZLAB, its debt to operating expenses ratio is greater than that reported by merely 9.12% of US equities we're observing.
  • ZLAB's price/sales ratio is 14.33; that's higher than the P/S ratio of 92.59% of US stocks.
  • ZLAB's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 12.31% of US stocks.
  • If you're looking for stocks that are quantitatively similar to ZAI LAB LTD, a group of peers worth examining would be VYNE, MIRM, PGEN, LGVN, and API.
  • Visit ZLAB's SEC page to see the company's official filings. To visit the company's web site, go to

ZLAB Valuation Summary

  • ZLAB's EV/EBIT ratio is -6; this is 150% lower than that of the median Healthcare stock.
  • Over the past 69 months, ZLAB's price/earnings ratio has gone up 28.4.

Below are key valuation metrics over time for ZLAB.

Stock Date P/S P/B P/E EV/EBIT
ZLAB 2023-05-23 14.3 3.3 -8.1 -6.0
ZLAB 2023-05-22 14.5 3.3 -8.2 -6.1
ZLAB 2023-05-19 13.3 3.1 -7.5 -5.4
ZLAB 2023-05-18 13.3 3.1 -7.5 -5.4
ZLAB 2023-05-17 14.2 3.3 -8.0 -5.9
ZLAB 2023-05-16 14.3 3.3 -8.0 -5.9

ZLAB's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ZLAB has a Quality Grade of C, ranking ahead of 42.52% of graded US stocks.
  • ZLAB's asset turnover comes in at 0.071 -- ranking 289th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows ZLAB's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.071 0.653 -5.744
2020-12-31 0.059 0.658 -0.531
2020-06-30 0.058 0.727 -0.851
2020-06-30 0.058 0.727 -0.851
2019-12-31 0.040 0.711 -0.887
2019-12-31 0.040 0.711 -0.889

Zai Lab Ltd. ADR (ZLAB) Company Bio

Zai Lab is an innovative, research-based, commercial stage biopharmaceutical company based in China and the U.S. focused on bringing transformative medicines for oncology, autoimmune disorders, infectious diseases and neurological disorders to patients in China and around the world. Our longer-term goal is to leverage our China-based competencies and resources to enable and impact human health worldwide. (Source:ZaiLaborator)

ZLAB Latest News Stream

Event/Time News Detail
Loading, please wait...

ZLAB Latest Social Stream

Loading social stream, please wait...

View Full ZLAB Social Stream

Latest ZLAB News From Around the Web

Below are the latest news stories about ZAI LAB LTD that investors may wish to consider to help them evaluate ZLAB as an investment opportunity.

Why Shares of Alibaba, PDD, and Zai Lab Are Rising Today

Several Chinese stocks rose today after positive sentiment from Wall Street and recent comments made by President Biden.

Yahoo | May 22, 2023

Zai Lab Announces That Repotrectinib Granted Priority Review by China’s NMPA

SHANGHAI, China and CAMBRIDGE, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted priority review to repotrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small-cell lung cancer (NSCLC). “The CDE’s decision to grant priority review to repotrectinib underscores repotrectinib as a potential

Yahoo | May 18, 2023

Investors push Zai Lab (NASDAQ:ZLAB) 9.3% lower this week, company's increasing losses might be to blame

It might be of some concern to shareholders to see the Zai Lab Limited ( NASDAQ:ZLAB ) share price down 13% in the last...

Yahoo | May 15, 2023

Mirati (MRTX) Q1 Earnings & Revenues Beat Estimates, Stock Up

Mirati (MRTX) reports better-than-expected first-quarter results, wherein earnings and revenues beat estimates. The stock climbs 2% on Tuesday. Pipeline development is on track.

Yahoo | May 10, 2023

Zai Lab Announces First Quarter 2023 Financial Results and Corporate Updates

Total product revenue of $62.8 million for the first quarter of 2023, representing a 36% increase y-o-y; ZEJULA® achieved 44% y-o-y growth Expansion of Zai Lab’s lung cancer franchise and global oncology pipeline with a next generation antibody-drug conjugate (ADC) program Strong balance sheet with a cash position of $931.4 million as of March 31, 2023, compared to $1,009.3 million as of December 31, 2022Company to host conference call and webcast on May 10, 2023, at 8:00 a.m. ET SHANGHAI and CA

Yahoo | May 9, 2023

Read More 'ZLAB' Stories Here

ZLAB Price Returns

1-mo -4.00%
3-mo -9.56%
6-mo -8.72%
1-year 14.78%
3-year -55.11%
5-year 42.80%
YTD 8.79%
2022 -51.15%
2021 -53.56%
2020 225.41%
2019 79.11%
2018 9.37%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!